
Aziyo Biologics AZYO
Annual report 2025
added 03-13-2026
Aziyo Biologics Total Assets 2011-2026 | AZYO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Aziyo Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62.4 M | 36.1 M | 43.4 M | 68.8 M | 67.2 M | 82.8 M | 44.8 M | 47.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.8 M | 36.1 M | 56.7 M |
Quarterly Total Assets Aziyo Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 M | 33.8 M | 39.3 M | 48.4 M | 41.9 M | 35.4 M | 54.6 M | 52.3 M | 60.6 M | 68.8 M | 61 M | 52.9 M | 59.9 M | 67.2 M | 59.9 M | 69.7 M | 74.2 M | 82.8 M | 82.8 M | 82.8 M | 82.8 M | 44.8 M | 44.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82.8 M | 29.4 M | 57.8 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
7.36 M | $ 2.24 | 0.9 % | $ 3.5 M | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 10.47 | 0.19 % | $ 1.41 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 12.56 | -3.75 % | $ 1.88 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
97.7 M | $ 9.61 | -13.93 % | $ 272 M | ||
|
Cognyte Software Ltd.
CGNT
|
498 M | $ 8.37 | 0.12 % | $ 601 M | ||
|
Butterfly Network
BFLY
|
256 M | $ 3.95 | -7.49 % | $ 836 M | ||
|
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.65 | -4.41 % | $ 35.4 M | ||
|
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 71.28 | 0.11 % | $ 106 B | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.92 | -3.21 % | $ 146 M | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 36.71 | -1.69 % | $ 1.14 B | ||
|
Establishment Labs Holdings
ESTA
|
357 M | $ 65.5 | 0.75 % | $ 1.94 B | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
199 M | $ 18.44 | -0.05 % | $ 121 M | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
766 M | $ 13.45 | -1.47 % | $ 869 M | ||
|
Abbott Laboratories
ABT
|
86.7 B | $ 108.49 | -2.04 % | $ 189 B | ||
|
Delcath Systems
DCTH
|
124 M | $ 9.38 | -3.7 % | $ 336 M | ||
|
Bio-Rad Laboratories
BIO
|
9.36 B | $ 267.99 | -0.55 % | $ 7.56 B | ||
|
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.07 | -4.61 % | $ 1.26 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 8.9 | -2.2 % | $ 685 M | ||
|
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.33 | - | $ 21.5 M | ||
|
AxoGen
AXGN
|
222 M | $ 30.94 | -5.53 % | $ 1.42 B | ||
|
Align Technology
ALGN
|
6.21 B | $ 172.41 | -2.11 % | $ 12.9 B | ||
|
Bruker Corporation
BRKR
|
5.81 B | $ 34.03 | 0.86 % | $ 5.07 K | ||
|
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
66.8 M | $ 3.67 | -1.87 % | $ 151 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 16.66 | -3.2 % | $ 391 M | ||
|
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
470 M | $ 0.41 | 5.24 % | $ 42.1 M | ||
|
IRadimed Corporation
IRMD
|
109 M | $ 99.67 | -3.04 % | $ 1.27 B |